1998
DOI: 10.1002/(sici)1097-4644(19980601)69:3<271::aid-jcb5>3.3.co;2-7
|View full text |Cite
|
Sign up to set email alerts
|

Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen‐independent progression in the human prostate LNCaP tumor model

Abstract: Progression to androgen independence remains the main obstacle to improving survival and quality of life in patients with advanced prostate cancer. Induction of differentiation may serve as a rational basis for prevention of progression to androgen independence by modulating gene expression activated by castration or upregulated during androgen-independent progression. The objectives of this study were to characterize the in vitro effects of sodium butyrate on human prostate cancer cell growth, PSA gene expres… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
19
0

Year Published

2000
2000
2014
2014

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 14 publications
(21 citation statements)
references
References 20 publications
2
19
0
Order By: Relevance
“…These effects are reminiscent of other agents reported to block the proliferation of prostate cancer cells in vitro and in vivo, most notable the histone deactylase inhibitors (HDACi). Using the LNCaP tumour model, sodium butyrate caused G 1 cell-cycle arrest, inhibited LNCaP cell growth and increased PSA gene expression (Kruh, 1982;Gleave et al, 1998). Similar findings with respect to inhibition of cell proliferation and PSA secretion have been reported for vitamin D 3 (Esquenet et al, 1996), calcitriol (Bauer et al, 2003), activin A, (Fujii et al, 2004) and phenylacetate (Walls et al, 1996).…”
Section: Discussionsupporting
confidence: 70%
“…These effects are reminiscent of other agents reported to block the proliferation of prostate cancer cells in vitro and in vivo, most notable the histone deactylase inhibitors (HDACi). Using the LNCaP tumour model, sodium butyrate caused G 1 cell-cycle arrest, inhibited LNCaP cell growth and increased PSA gene expression (Kruh, 1982;Gleave et al, 1998). Similar findings with respect to inhibition of cell proliferation and PSA secretion have been reported for vitamin D 3 (Esquenet et al, 1996), calcitriol (Bauer et al, 2003), activin A, (Fujii et al, 2004) and phenylacetate (Walls et al, 1996).…”
Section: Discussionsupporting
confidence: 70%
“…It is a potent growth inhibitor and initiates cell differentiation in several cell types, including breast cancer cells in vitro (Coradini et al 1997, Velázquez et al 1997, Gleave et al 1998, Yamamoto et al 1998. Although the molecular mechanisms by which butyrate exerts its effects are still unclear, it is known to induce a number of alterations within the nucleus, including histone hyperacetylation (de Haan et al 1986, Archer & Hodin 1999.…”
Section: Introductionmentioning
confidence: 99%
“…Such compounds are for example butyrates, members of the group of histone deacetylase inhibitors (HDACs) (Gleave et al, 1998). Butyrates are naturally occurring short-chain fatty acids leading to differentiation of numerous cell types (Chen and Breitman, 1994).…”
mentioning
confidence: 99%